A novel interaction between calretinin and AMPA [(S)-2 amino-3-(3-hydroxy-5-methyl-4-isoazolyl)-propionic-acid] has been proposed as a potential target for the development of new antipsychotic therapeutics for schizophrenia (Siekmeier and vanMaanen, 2013). Here, CALB2 is linked to schizophrenia.